Spinal Muscular Atrophy (SMA): Causes, Types, Symptoms, and Treatments
Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by homozygous loss-of-function mutations in SMN1 (survival motor neuron 1) on chromosome 5q13. This leads to deficiency of SMN protein—essential for motor neuron survival.
Genetics
- SMN1 deletion/mutation: Accounts for >95% of cases (exon 7 deletion most common)
- SMN2 copy number modifies severity: SMN2 produces only ~10–15% functional SMN; more copies generally mean milder phenotype
- Carrier frequency: ~1/40–1/60 across ethnicities
- Inheritance: Autosomal recessive (25% recurrence risk if both parents are carriers)
Classification by Onset and Maximum Motor Function (Natural History)
| Type | Onset | Max Motor Milestone | Life Expectancy (Untreated) |
|---|---|---|---|
| Type 0 (Prenatal) | Fetal | None; arthrogryposis | Perinatal |
| Type 1 (Werdnig-Hoffmann) | <6 months | Never sits independently | <2 years (respiratory failure) |
| Type 2 (Dubowitz) | 6–18 months | Sits; never walks independently | Adulthood (with respiratory support) |
| Type 3 (Kugelberg-Welander) | >18 months | Walks; may lose ability later | Normal |
| Type 4 (Adult-onset) | Adulthood | Walks; slow progression | Normal |
Clinical Features
- Symmetric proximal > distal weakness
- Hypotonia, areflexia, fasciculations (especially tongue)
- Bell-shaped chest, paradoxical breathing (Type 1)
- Scoliosis, hip dislocation, contractures
- Bulbar weakness: swallowing and speech difficulties
- Intact cognition and sensation
Disease-Modifying Therapies (Transformative Since 2016)
- Nusinersen (Spinraza®): Antisense oligonucleotide splicing modifier → increases SMN2 exon 7 inclusion; intrathecal every 4 months after loading; all types
- Risdiplam (Evrysdi®): Oral daily splicing modifier; all ages and types; home administration
- Onasemnogene abeparvovec (Zolgensma®): AAV9-SMN1 gene replacement; single IV dose; <2 years (weight-based); highest impact in pre-symptomatic/Type 1
Supportive Care (Essential Alongside DMTs)
- Respiratory: NIV, cough assist, secretion clearance, vaccination
- Nutritional: G-tube if dysphagia; reflux management
- Orthopedic: Scoliosis bracing/surgery; contracture prevention
- Rehabilitation: PT/OT/Aqua therapy; maintain function, prevent disuse atrophy
- Multidisciplinary clinic: Neuromuscular, pulmonology, orthopedics, GI, genetics, palliative care
Newborn Screening
- Now universal in the US (all 50 states) and many countries
- Enables pre-symptomatic treatment—dramatically alters disease trajectory
Prognosis
With early treatment (especially pre-symptomatic), motor milestones are achieved, survival is normalized, and ventilation is avoided in many patients. Long-term durability and combination therapies remain under active study.
Bones, Joints & Muscles - Related Articles
- Finger Arthritis Treatment: Understanding & Relief
- Understanding Hand Tremors and Joint Pain: Causes & Connections
- Muscle Locations in the Human Body: Types, Functions, and Control
- Cortical vs. Cancellous Bone: Structure, Function, and Clinical Significance
- Clavicle Bone Marrow Edema: Diagnosis, Symptoms & What to Expect
- Effective Shoulder Therapy Exercises for Pain & Recovery
- Understanding Duchenne Muscular Dystrophy (DMD): Symptoms & Overview
